Managing multiple myeloma in elderly patients Journal Article


Authors: Diamond, E.; Lahoud, O. B.; Landau, H.
Article Title: Managing multiple myeloma in elderly patients
Abstract: Multiple myeloma (MM) is a plasma cell neoplasm that affects elderly individuals with two-thirds of patients over 65 years at diagnosis. However, data available are derived from clinical trials conducted in younger patients. Fewer studies investigated treatment options in the elderly. This review summarizes the clinical outcomes and toxicities associated with therapeutic regimens in older patients including doublet, triplet and high dose therapyin newly diagnosed patients and relapsed patients with MM. We highlight the importance of an approach tailored to individuals, incorporates the geriatric frailty assessment, considers comorbiditiess and commits to early recognition and management of toxicities ranging from myelosuppression to polypharmacy. To date, no trial has prospectively investigated a tailored treatment paradigm in older patients based on frailty and/or comorbidities. As the population ages, the proportion of MM patients with advanced age will grow. Studies are indicated to determine optimal treatment approaches in this increasingly heterogeneous geriatric population. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: toxicity; geriatric; dose reduction; dose modification; dose adjustment; transplant ineligible
Journal Title: Leukemia and Lymphoma
Volume: 59
Issue: 6
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2018-01-01
Start Page: 1300
End Page: 1311
Language: English
DOI: 10.1080/10428194.2017.1365859
PROVIDER: scopus
PUBMED: 28847191
DOI/URL:
Notes: Review -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Heather Jolie Landau
    173 Landau
  2. Oscar Boutros Lahoud
    5 Lahoud